Skip to main content
TipRanks
Go Ultimate75% OFF

Proteome Sciences (PRM) AI Stock Analysis

3 Followers
GB:PRM

Proteome Sciences

(LSE:PRM)

Select Model
Rating:39Underperform
Price Target:GBX 1.00â–¼(-26.47% Downside)
Action:reiterated
Date:11/05/26

The overall score is very low, driven primarily by the company's dire financial state, including negative equity and persistent losses. Technical trends are bearish, and the negative P/E ratio confirms a lack of underlying profitability. The company faces significant solvency risks, making it a highly speculative investment.

Positive Factors
Specialized Proteomics OfferingThe company operates in a specialized proteomics niche that directly supports drug discovery and biomedical research. Its combination of analytical services, mass spectrometry workflows, and bioinformatics gives it a defined offering for pharmaceutical, biotechnology, and academic customers over the medium term.
Negative Factors
Severe Solvency PressureThe combination of rising debt, deeply negative equity, and assets below total debt indicates a capital structure under significant strain. This reduces financial flexibility and leaves the company more exposed to refinancing requirements, potential dilution, and constraints on funding its operating plans.

Proteome Sciences (PRM) vs. iShares MSCI United Kingdom ETF (EWC)

-25%0%25%50%75%100%125%GB:PRM-18.81%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 4.77M
Dividend Yield
―
Average Volume (3M)
188.53K
Price to Earnings (P/E)
-1.9
Beta (1Y)
0.19
Revenue Growth
-16.72%
EPS Growth
36.28%
Country
UK
Employees
32
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

Proteome Sciences Business Overview & Revenue Model

Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standa...

Proteome Sciences Financial Statement Overview

Summary

Financial health is critically weak. Declining revenues, negative gross margins, negative shareholders' equity, and a debt-to-asset ratio of 1.9 indicate severe financial distress. The only positive is an improving cash flow trend, but it remains negative.

Income Statement

15Very Negative

Balance Sheet

5Very Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.77M3.76M4.89M5.03M7.78M5.12M
Gross Profit-956.00K-1.01M-167.00K1.16M4.77M2.96M
EBITDA-1.30M-1.74M-1.52M-1.14M2.01M625.00K
Net Income-2.32M-3.06M-3.41M-2.44M1.32M72.00K
Balance Sheet
Total Assets7.67M8.26M9.21M11.46M12.43M10.04M
Cash, Cash Equivalents and Short-Term Investments1.10M781.00K1.13M2.03M3.99M2.39M
Total Debt15.95M15.77M14.52M13.47M11.91M11.69M
Total Liabilities17.57M17.79M15.72M14.52M13.28M12.82M
Stockholders Equity-9.90M-9.53M-6.52M-3.07M-843.00K-2.77M
Cash Flow
Free Cash Flow367.00K-143.00K-1.05M-718.00K2.14B8.80B
Operating Cash Flow425.00K-46.00K-826.00K-481.00K3.88B10.52B
Investing Cash Flow-56.00K-97.00K-224.00K-424.00K-21.67B4.27B
Financing Cash Flow461.00K-204.00K151.00K-1.06M-209.00K-400.00K

Proteome Sciences Technical Analysis

Technical Analysis SentimentNegative
Last Price1.36

Price Trends

50DMA1.41Negative
100DMA1.57Negative
200DMA1.61Negative

Market Momentum

MACD-0.01Positive
RSI46.39Neutral
STOCH36.19Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Negative. The current price of 1.36 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.41, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.39 is Neutral, neither overbought nor oversold. The STOCH value of 36.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRM.

Proteome Sciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:PRM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:GDRGB:GDR49NeutralGBP 14.45M-0.82-1044.57%―65.60%74.84%
GB:CLBXGB:CLBX48NeutralGBP 6.82M-0.49-104.73%―-56.10%41.10%
GB:GENIGB:GENI40UnderperformGBP 4.52M-0.45-481.34%―-10.81%42.67%
GB:PRMGB:PRM39UnderperformGBP 4.77M-1.8623.85%―-16.72%36.28%
GB:VRCIGB:VRCI38UnderperformGBP 13.66M-0.53-127.57%―77.87%84.36%
GB:OPTIGB:OPTI32UnderperformGBP 4.70M-1.10-77.85%―11.90%-2864.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%GB:PRMGB:CLBXGB:GDRGB:OPTIGB:VRCIGB:GENIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:PRM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:PRMProteome Sciences1.36-0.29-17.58%
GB:CLBXANGLE plc0.60-1.20-66.67%
GB:GDRGenedrive plc0.900.1113.92%
GB:OPTIOptiBiotix Health4.55-3.70-44.85%
GB:VRCIVerici Dx Plc0.20-0.57-73.55%
GB:GENIGENinCode UK Ltd.0.60-1.70-73.91%

Proteome Sciences Corporate Events

Business Operations and StrategyExecutive/Board Changes

Proteome Sciences Adds Former KPMG International CFO Helen Spice to Board

Positive
Sep 16, 2026

Proteome Sciences plc has strengthened its board with the appointment of Helen Spice as an independent non-executive director, effective immediately. Spice, a former CFO of KPMG International and current non-executive director at Barts Health NHS Tru...

Business Operations and StrategyFinancial Disclosures

Proteome Sciences Builds Order Book as Targeted Proteomics Demand and TMT Sales Rise

Positive
Sep 16, 2026

Proteome Sciences reported interim revenues of £1.87m for the first half of 2026, broadly flat year-on-year, with lower services income offset by stronger TMT reagent sales and royalties, and an improved gross profit thanks to reduced costs. Manageme...

Business Operations and Strategy

Proteome Sciences Wins Major GCLP Chemoproteomics Contract for Global Clinical Trials

Positive
Sep 15, 2026

Proteome Sciences has secured a significant new clinical chemoproteomics contract that will be conducted under Good Clinical Laboratory Practice at its Frankfurt laboratories. The engagement, linked to the same protein studied in two earlier projects...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026